Siemens Healthineers Hovers Above Critical Support as Diagnostics Unit Plunges Into Crisis

Siemens Healthineers shares hover near €33.50 support as diagnostics margin collapses to 0.9%, CEO prepares carve-out, guidance cut, and analysts split on recovery.

Siemens Healthineers shares are clinging to a knife-edge near their 52-week low, closing Friday at €33.59 — barely a whisker above the May trough of €33.50. Down roughly 24% since the start of the year and trading more than 20% below its 200-day moving average, the medical technology group is wrestling with the deepest restructuring in its history. The stock’s distance from its 52-week high of €49.86 now stands at almost 33%, and the immediate question is whether the €33.50 support level can hold.

The root of the malaise lies in the diagnostics segment. In the latest quarter, the unit’s adjusted operating margin collapsed to just 0.9%, hammered by structural problems in China where lower reimbursement rates are squeezing revenues. While the imaging division grew 6.1% and the cancer-therapy arm Varian advanced 7.5%, diagnostics acted as a dead weight. CEO Bernhard Montag is now preparing a carve-out of the business — a standalone structure that keeps all options open, from a full sale to an initial public offering.

The Asian headwinds have forced management to trim full-year guidance. Comparable revenue growth is now expected to land between 4.5% and 5.0%, down from a prior forecast of up to six percentage points. Adding to the pressure on the home front, the German cabinet is planning a multibillion-euro austerity package for the healthcare system, with hospitals — Siemens Healthineers’ biggest buyers of imaging gear — bearing the brunt of the cuts.

The broader competitive landscape offers little comfort. Chinese rival Mindray Medical suffered a revenue decline of nearly 10% in fiscal 2025 and a profit plunge of over 30%. Meanwhile, GE HealthCare faces its own supply-chain bottlenecks, rising costs and regulatory friction around artificial intelligence applications. That last issue directly threatens Siemens Healthineers’ heavy investments in AI-powered diagnostics. At the German Medical Association’s congress in Hannover in May 2026, doctors warned against weakening data protection and demanded strict rules for autonomous AI agents. Tighter EU regulations could delay or inflate the cost of product approvals in Europe.

Analysts are split on the stock’s prospects. Jefferies retains a buy rating but has cut its price target to €50. Deutsche Bank is more cautious, keeping a “hold” with a fair-value estimate of €38 and calling for a clear revival in growth. The consensus target among analysts hovers around €49.

On the charts, the relative strength index sits at 69, hinting at a possible short-term bounce, but the overarching downtrend remains intact. The 200-day moving average at roughly €43 is more than 20% above the current price, underscoring the severity of the sell-off. A decisive break below €33.50 would leave the stock without a clear technical floor.

The longer-term story revolves around the parent company Siemens AG, which plans to hold a vote on a full spin-off of Siemens Healthineers, likely in early 2027. Until then, the core imaging and therapy divisions are expected to keep the operational engine running. Management has promised adjusted earnings growth even without a swift recovery in China. But with diagnostics in surgery and regulatory clouds gathering over AI, investors are demanding more than promises.